Rhumbline Advisers Has $2.58 Million Stock Holdings in Certara, Inc. $CERT

Rhumbline Advisers trimmed its stake in shares of Certara, Inc. (NASDAQ:CERT) by 6.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 260,454 shares of the company’s stock after selling 16,998 shares during the quarter. Rhumbline Advisers owned approximately 0.16% of Certara worth $2,578,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC bought a new stake in Certara during the 1st quarter worth approximately $120,000. Illinois Municipal Retirement Fund boosted its stake in shares of Certara by 3.9% in the 1st quarter. Illinois Municipal Retirement Fund now owns 59,721 shares of the company’s stock valued at $591,000 after purchasing an additional 2,268 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Certara by 4.5% in the 1st quarter. Northern Trust Corp now owns 916,299 shares of the company’s stock valued at $9,071,000 after purchasing an additional 39,289 shares during the last quarter. Brown Advisory Inc. bought a new position in Certara during the first quarter worth $238,000. Finally, Principal Financial Group Inc. boosted its stake in Certara by 2.4% during the first quarter. Principal Financial Group Inc. now owns 543,958 shares of the company’s stock worth $5,385,000 after acquiring an additional 12,513 shares in the last quarter. 73.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

CERT has been the topic of several research analyst reports. Zacks Research raised shares of Certara from a “strong sell” rating to a “hold” rating in a research note on Friday, September 5th. Morgan Stanley initiated coverage on shares of Certara in a report on Thursday, July 3rd. They issued an “equal weight” rating and a $16.00 target price for the company. KeyCorp lowered their target price on shares of Certara from $18.00 to $15.00 and set an “overweight” rating for the company in a report on Monday, July 14th. Finally, UBS Group lowered their target price on shares of Certara from $17.50 to $15.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Five analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $15.14.

Certara Price Performance

CERT stock opened at $11.55 on Wednesday. The firm has a 50 day moving average of $10.74 and a 200-day moving average of $11.26. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.27. Certara, Inc. has a 12 month low of $8.64 and a 12 month high of $15.69. The firm has a market capitalization of $1.86 billion, a P/E ratio of 231.05 and a beta of 1.43.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a net margin of 1.97% and a return on equity of 5.11%. The firm had revenue of $104.57 million during the quarter, compared to the consensus estimate of $104.14 million. During the same quarter last year, the business posted $0.07 earnings per share. Certara’s revenue was up 12.1% compared to the same quarter last year. As a group, sell-side analysts predict that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Insider Activity at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total value of $559,366.08. Following the completion of the transaction, the insider directly owned 73,979 shares in the company, valued at approximately $807,850.68. This trade represents a 40.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.33% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.